AstraZeneca announced that it could face a fine of up to $4.5 million in China over suspected unpaid import taxes, a figure significantly lower than some investors had feared. The ...
AstraZeneca’s planned vaccine hub for Liverpool is off the table - business editor Karl Matchett and Whitehall editor Kate ...
If the trial is successful, the firm's complete estrogen receptor antagonist would complement its other biomarker-driven breast cancer assets.
A pharma industry group asked the FDA to "take action" against a "dangerous" ad Hims & Hers plans to run during the Super ...
How an agreement set up by the Tories and lauded by Labour fell victim to cost-cutting and UK curbs on drugs expenditure ...
The FDA approved Datroway to treat metastatic or unresectable HR+/HER2- breast cancer in people who have tried standard chemo ...
In addition to the UK investment controversy, AstraZeneca is also dealing with legal challenges in China. The company ...
Oncology revenue reached $22.4 billion in 2024, with Tagrisso, Lynparza, and Enhertu delivering strong growth. Enhertu's revenue grew 54% in Q4, supported by expanded indications, including HER2 low ...
AstraZeneca reports mixed results in the fourth quarter. It gains in pre-market after assuring investors that the business ...